ProSomnus SPAC Presentation Deck

Too Many People Globally Continue to suffer from OSA We believe that ProSomnus is poised to disrupt the large and growing OSA market benefiting from the improving diagnosis rates, while presenting a preferred alternative to existing therapies Expected increase in diagnosis rates driven by physician and general population awareness of OSA with large undiagnosed population Significant number of patients who have failed CPAP in North America alone, with failure rate of ~50%5 Increase in consumer-friendly therapies and devices such as those from Align, Dexcom and Inspire Major shift occurring towards at-home testing and remote monitoring, facilitating access to care LARGE AND GROWING OPPORTUNITY 2009 1. 2. 5% 3. OSA DIAGNOSIS RATES ARE TRENDING HIGHER 3 20% 2019 Significant untapped opportunity as rate of diagnosis continues to expand 100% Benjafield AV et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature- based analysis. Lancet Respir Med. 2019 Aug 7. Cites that as of 2019 an estimated 936 million adults aged 30-69 have mild to moderate OSA, as such we estimate >1 billion global OSA sufferers Assumes 32% prevalence of OSA (Benjafield et al. 2019 Aug 7), multiplied by North American adult population of approximately 230 million as provided by OECD Diagnosis rate of ~20%, cited in Harvard Medical School. THE PRICE OF FATIGUE. December, 2010, with assumed increase of approximately 400 basis points by 2020 5. 6. TOTAL ADDRESSABLE MARKET (POPULATION) Global OSA Sufferers North American OSA Sufferers North American OSA Diagnoses North American CPAP Users 4. Approximated using 18mm North American diagnoses and ~80% CPAP modality prescription rate (cited in Harvard Medical School. THE PRICE OF FATIGUE. December, 2010) Represents North American market failures of ~50% cited in Catcheside PG. Predictors of continuous positive airway pressure adherence. F1000 Med Rep. 2010 Sep 23 Calculated as 18mm diagnosed North American sufferers multiplied by the CPAP modality prescription rate of ~80% (Harvard: December 2010), multiplied by the CPAP therapy failure rate of ~50% (Catcheside PG. 2010 Sep 23) PROSOMNUS SLEEP TECHNOLOGIES Failed CPAP >1bn¹ ~74mm² ~18mm³ ~15mm4 ~7mm6 9 STRICTLY CONFIDENTIAL

View entire presentation